Trials / Completed
CompletedNCT00080015
Diflomotecan (BN80915) Administered Once Every 3 Weeks in Treating Patients With Sensitive Small Cell Lung Cancer (SCLC)
A Phase II Open Label Study Investigating the Activity of Diflomotecan (BN80915) Administered at the Fixed Dose of 7mg as a 20 Minute Intravenous Infusion Once Every 3 Weeks in Patients With Sensitive Small Cell Lung Cancer (SCLC) Who Have Failed First-line Treatment With a Platinum Based Regimen.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 9 (actual)
- Sponsor
- Ipsen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase II, open-label, multicenter, single-arm, exploratory "proof of concept" study. Diflomotecan (7 mg fixed dose) will be administered as a 20-minute IV infusion once every 3 weeks in patients with sensitive small cell lung cancer (SCLC) with progressive disease after first-line treatment with a platinum-based regimen.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Diflomotecan (BN80915) |
Timeline
- Start date
- 2004-03-12
- Primary completion
- 2005-02-01
- Completion
- 2005-02-01
- First posted
- 2004-03-23
- Last updated
- 2020-04-29
Source: ClinicalTrials.gov record NCT00080015. Inclusion in this directory is not an endorsement.